Our Approach
The heart of our approach is using collaboration to assemble a powerful structure-based drug discovery engine. Our ‘special sauce’ is applying that engine and our unique collective expertise to drive target selection and the design of novel molecules that become breakthrough medicines.
Target Selection
We identify targets known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. Our targets play causal roles in diseases of immunology, oncology and metabolism; drugging them with efficacious small molecules has the potential to transform patients’ lives.
Target Selection
We identify targets known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle. Our targets play causal roles in diseases of immunology, oncology and metabolism; drugging them with efficacious small molecules has the potential to transform patients’ lives.
Structure-Based Drug Discovery Engine
We apply leading-edge computational chemistry, in concert with other technologies, to more effectively use high-resolution protein structural data to drug targets and modulate their functional activity.
Structure-Based Drug Discovery Engine
We apply leading-edge computational chemistry, in concert with other technologies, to more effectively use high-resolution protein structural data to drug targets and modulate their functional activity.
Structural Biology
We deploy a range of technologies, including X-ray crystallography and cryo-electron microscopy (cryo-EM) to generate atomic-resolution structural data on our targets — in some cases, for proteins that have never before been successfully mapped.
Structural Biology
We deploy a range of technologies, including X-ray crystallography and cryo-electron microscopy (cryo-EM) to generate atomic-resolution structural data on our targets — in some cases, for proteins that have never before been successfully mapped.
Computational Chemistry
We leverage the technology and deep expertise of our founding partner Schrödinger and other technology leaders to perform physics-based analyses of our targets’ active and allosteric sites and to design small molecule modulators with the desired binding mode, functional activity and selectivity.
Computational Chemistry
We leverage the technology and deep expertise of our founding partner Schrödinger and other technology leaders to perform physics-based analyses of our targets’ active and allosteric sites and to design small molecule modulators with the desired binding mode, functional activity and selectivity.
Molecular Sciences
Our comprehensive expertise spans protein science, biophysics, enzymology and screening. This assures optimization of our therapeutic candidates across a stringent set of drug-like properties.
Molecular Sciences
Our comprehensive expertise spans protein science, biophysics, enzymology and screening. This assures optimization of our therapeutic candidates across a stringent set of drug-like properties.
Breakthroughs by Design
Our resulting potent and selective small molecule compounds provide the means for us to gain a deeper understanding of biology and develop new therapies for clinical evaluation in patients.
Breakthroughs by Design
Our resulting potent and selective small molecule compounds provide the means for us to gain a deeper understanding of biology and develop new therapies for clinical evaluation in patients.